Cellectis Stock

Cellectis Gross Margin

The Gross Margin of Cellectis (ALCLS.PA) as of Sep 10, 2026 is 6.96 %. In the previous year, Gross Margin was -331.61 % — a change of -102.10% (higher).

Gross Margin

6.96 %

YoY

-102.10%

Last updated:

Gross Margin of Cellectis is 2026 6.96 % . Gross Margin of Cellectis was 2025 -331.61 % . It decreases by -102.10% higher compared to the previous year.

For Cellectis, the gross margin of 7.0% is down versus 22.6% a few years ago.

The Cellectis Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
-41.17 USD
Jan 1, 2018
-155.27 USD
Jan 1, 2019
-163.95 USD
Jan 1, 2020
22.63 USD
Jan 1, 2021
-71.15 USD
Jan 1, 2022
-72.78 USD
Jan 1, 2023
-331.61 USD
Jan 1, 2024
6.96 USD
The Cellectis Gross Margin history
YEARGross MarginYoY
6.96 %-102.10%
-331.61 %+355.63%
-72.78 %+2.29%
-71.15 %-414.47%
22.63 %-113.80%
-163.95 %+5.59%
-155.27 %+277.12%
-41.17 %-216.95%
35.20 %-43.35%
62.14 %+1.89%
60.99 %-7,870.39%
-0.78 %+255.06%
-0.22 %-71.94%
-0.79 %+89.68%
-0.42 %-28.71%
-0.58 %-165.06%
0.90 %+195.53%
0.30 %-120.62%
-1.47 %-336.59%
0.62 %
Access this data via the Eulerpool API

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Gross Margin of Cellectis is 6.96 % in 2026.

Gross Margin of Cellectis changed from -331.61 % to 6.96 %, representing a -102.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Cellectis since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Cellectis

All Key Metrics — Cellectis